Statistiche di base
| LEI | 549300FIWOFSETIVMI17 |
| CIK | 725363 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CEL-SCI Corp. Warrants
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 29, 2025 |
CEL-SCI ANNOUNCES CLOSING OF $10 MILLION PUBLIC OFFERING EXHIBIT 99.2 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $10 MILLION PUBLIC OFFERING Vienna, Virginia – August 29, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, |
|
| August 29, 2025 |
CEL-SCI CORPORATION Common Stock EXHIBIT 99 CEL-SCI CORPORATION Common Stock This Prospectus relates to shares (the "Shares") of common stock (the "Common Stock") of CEL-SCI Corporation which may be issued pursuant to certain employee compensation plans adopted by CEL-SCI. |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 27, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 29, 2025 |
CEL-SCI ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERING EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERING Vienna, Virginia – August 27, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, |
|
| August 29, 2025 |
CEL-SCI CORPORATION 2025 STOCK BONUS PLAN EXHIBIT 4(c) CEL-SCI CORPORATION 2025 STOCK BONUS PLAN l. Purpose. The purpose of this Stock Bonus Plan is to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for the successful conduct of its business, |
|
| August 29, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables S-8 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) 133,334 $ 13. |
|
| August 29, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off |
|
| August 29, 2025 |
PLACEMENT AGENCY AGREEMENT CEL-SCI CORPORATION THINKEQUITY LLC EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC 1 CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York August 27, 2025 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC ("ThinkEquity" or the "Placement Agent") shall |
|
| August 29, 2025 |
CEL-SCI CORPORATION 2025 NON-QUALIFIED STOCK OPTION PLAN EXHIBIT 4(b) CEL-SCI CORPORATION 2025 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the "Plan") is intended to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for th |
|
| August 28, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-288515 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 12, 2025) 1,111,200 Shares Common Stock CEL-SCI Corporation We are offering 1,111,200 shares of our common stock par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price of $9.00 per share. We have enga |
|
| August 27, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-288515 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus su |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 22, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI C |
|
| August 5, 2025 |
Amended Articles (reverse stock split only) EXHIBIT 3(f) CEL-SCI CORPORATION ATTACHMENT TO ARTICLES OF AMENDMENT The following is added to Article 4: Effective May 19, 2025, all outstanding shares of the Company’s common stock were combined on a 30-for-1 basis. Each outstanding share of the Company’s common stock will be combined into one share of common stock. |
|
| August 5, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-09l6344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and te |
|
| August 5, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) $ 100,000,000 $153. |
|
| July 14, 2025 |
CEL-SCI ANNOUNCES CLOSING OF $5.7 MILLION OFFERING PRICED AT-THE-MARKET UNDER NYSE AMERICAN RULES EXHIBIT 99.2 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $5.7 MILLION OFFERING PRICED AT-THE-MARKET UNDER NYSE AMERICAN RULES Vienna, Virginia – July 14, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinic |
|
| July 14, 2025 |
CEL-SCI ANNOUNCES PRICING OF $5.7 MILLION OFFERING PRICED AT-THE-MARKET UNDER NYSE AMERICAN RULES EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $5.7 MILLION OFFERING PRICED AT-THE-MARKET UNDER NYSE AMERICAN RULES Vienna, Virginia – July 11, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinic |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 11, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| July 14, 2025 |
EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC 1 CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York July 11, 2025 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC ("ThinkEquity" or the "Placement Agent") shall b |
|
| July 14, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 1,500,000 Shares Common Stock CEL-SCI Corporation We are offering 1,500,000 shares of our common stock par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price of $3.82 per share. We have engage |
|
| July 3, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) $ 100,000,000 $153. |
|
| July 3, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-09l6344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and telephone number i |
|
| July 3, 2025 |
Amended Articles (reverse stock split only) EXHIBIT 3(f) CEL-SCI CORPORATION ATTACHMENT TO ARTICLES OF AMENDMENT The following is added to Article 4: Effective May 19, 2025, all outstanding shares of the Company’s common stock were combined on a 30-for-1 basis. Each outstanding share of the Company’s common stock will be combined into one share of common stock. |
|
| May 23, 2025 |
CEL-SCI ANNOUNCES PRICING OF PUBLIC OFFERING EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF PUBLIC OFFERING Vienna, VA, May 21, 2025 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pr |
|
| May 23, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 21, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 23, 2025 |
CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING EXHIBIT 99.2 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING Vienna, VA, May 23, 2025 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the cl |
|
| May 23, 2025 |
EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC as Representative of the Several Underwriters CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York May 21, 2025 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: The undersigned, CEL-SCI Corp |
|
| May 22, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 2,000,000 Shares Common Stock CEL-SCI Corporation We are offering 2,000,000 shares of our common stock par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price of $2.50 per share. Our common sto |
|
| May 21, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus su |
|
| May 19, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 19, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI |
|
| April 9, 2025 | ||
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| March 18, 2025 |
EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York March 17, 2025 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC ("ThinkEquity" or the "Placement Agent") shall be |
|
| March 18, 2025 |
CEL-SCI ANNOUNCES CLOSING OF $2.5 MILLION OFFERING EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $2.5 MILLION OFFERING Vienna, Virginia – March 18, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing |
|
| March 18, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 4,012,500 Shares of Common Stock 11,987,500 Pre-Funded Warrants to Purchase Shares of Common Stock CEL-SCI Corporation We are offering 4,012,500 shares of our common stock par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus. The shares |
|
| March 18, 2025 |
EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT CEL-SCI CORPORATION Warrant Shares: 11,987,500 Issue Date: March 18, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, 3i, LP or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 17, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| March 18, 2025 |
CEL-SCI ANNOUNCES PRICING OF $2.5 MILLION OFFERING EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $2.5 MILLION OFFERING Vienna, Virginia – March 17, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing |
|
| March 3, 2025 |
HART & HART, LLC ATTORNEYS AT LAW 1624 Washington Street Denver, CO 80203 HART & HART, LLC ATTORNEYS AT LAW 1624 Washington Street Denver, CO 80203 (303) 839-0061 harttrinen@aol. |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-S |
|
| January 13, 2025 |
Insider Trading Policies and Procedures EXHIBIT 19 CEL-SCI CORPORATION Insider Trading Policy I. PURPOSE CEL-SCI Corporation (the “Company”) has adopted this Insider Trading Policy (this “Policy”) to help its directors and officers comply with insider trading laws, to prevent even the appearance of improper insider trading and to promote compliance with the Company’s obligation under Item 408 of Regulation S-K to publicly disclose infor |
|
| January 13, 2025 |
FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI CORPORATION (Exact |
|
| January 3, 2025 |
CEL-SCI CORPORATION 1,000,000 Shares of Common Stock 424(b)(3) File #333-282844 PROSPECTUS CEL-SCI CORPORATION 1,000,000 Shares of Common Stock This prospectus relates to the possible resale, from time to time, by the selling shareholder identified in this prospectus of up to 1,000,000 shares of our common stock, which were issued in partial payment of amounts owed for services in connection with our confirmatory Phase III clinical trial. |
|
| December 31, 2024 |
EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT CEL-SCI CORPORATION Warrant Shares: Issue Date: December, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and |
|
| December 31, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 29, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission F |
|
| December 31, 2024 |
EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York December 29, 2024 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC ("ThinkEquity" or the "Placement Agent") shall |
|
| December 31, 2024 |
CEL-SCI ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING Vienna, Virginia – December 29, 2024 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today |
|
| December 31, 2024 |
CEL-SCI ANNOUNCES CLOSING OF $5 MILLION OFFERING EXHIBIT 99.2 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $5 MILLION OFFERING Vienna, Virginia – December 31, 2024 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the c |
|
| December 30, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 7,552,500 Shares of Common Stock 8,577,500 Pre-Funded Warrants to Purchase Shares of Common Stock 8,577,500 Shares of Common Stock Underlying the Pre-Funded Warrants CEL-SCI Corporation We are offering 7,552,500 shares of our common stock par value $0.01 per share, pursuant to thi |
|
| December 30, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 NT 10-K 1 cvmnt10k.htm NT 10-K U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SEC File Number 001-11889 CUSIP Number 150837508 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR For Period Ended: September 30, 2024. ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q For the Transition Period E |
|
| December 27, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus su |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 13, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission F |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 12, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission F |
|
| November 5, 2024 |
CEL-SCI CORPORATION 8229 Boone Blvd. #802 Vienna, VA 22182 (703) 506-9460 November 5, 2024 CEL-SCI CORPORATION 8229 Boone Blvd. #802 Vienna, VA 22182 (703) 506-9460 November 5, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: CEL-SCI Corporation Form S-3 SEC File No. 333-282844 CEL-SCI Corporation (the “Company”) requests that the effective date of the above captioned Registration Statement be accelerated to Thursday, November 7, 2024 at 4:00 P.M. Easter |
|
| October 30, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and te |
|
| October 30, 2024 |
EXHIBIT 4 SECURITIES PURCHASE AGREEMENT between CEL-SCI CORPORATION and ERGOMED GROUP LIMITED dated as of October 18, 2024 1 TABLE OF CONTENTS ARTICLE I DEFINITIONS 4 ARTICLE II PURCHASE AND SALE 6 Section 2. |
|
| October 25, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and telephone number i |
|
| October 25, 2024 |
Calculation of Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) 1,000,000 $ 0. |
|
| October 11, 2024 |
Registration No 333-265995 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-09l6344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Nu |
|
| October 11, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables S-3 Post-Effective Amendment No. 1 (Form Type) Cel-Sci Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amou |
|
| October 10, 2024 |
CEL-SCI CORPORATION 8229 Boone Blvd. #802 Vienna, VA 22182 (703) 506-9460 October 10, 2024 CEL-SCI CORPORATION 8229 Boone Blvd. #802 Vienna, VA 22182 (703) 506-9460 October 10, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Amendment to Registration Statement on Form S-3 File No. 333-265995 CEL-SCI Corporation (the “Company”) requests that the above-captioned Amendment to its registration statement on Form S-3 filed on October 8, 2024 (File No. 333-265 |
|
| October 8, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables S-3 Post-Effective Amendment No. 1 (Form Type) Cel-Sci Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amou |
|
| October 8, 2024 |
Registration No 333-265995 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-09l6344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Nu |
|
| September 17, 2024 |
EXHIBIT 99 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation · 5-year survival rate of 82.6% and |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 16, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission |
|
| August 30, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off |
|
| August 30, 2024 |
EXHIBIT 99 CEL-SCI CORPORATION Common Stock This Prospectus relates to shares (the "Shares") of common stock (the "Common Stock") of CEL-SCI Corporation which may be issued pursuant to certain employee compensation plans adopted by CEL-SCI. |
|
| August 30, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables S-8 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) 2,000,000 $ 1. |
|
| August 30, 2024 |
Non-Qualified Stock Option Plan EXHIBIT 4(b) CEL-SCI CORPORATION 2024 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the "Plan") is intended to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for th |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SCI |
|
| July 29, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 3,715,000 Shares of Common Stock 7,130,000 Pre-Funded Warrants to Purchase Shares of Common Stock 7,130,000 Shares of Common Stock underlying the Pre-Funded Warrants CEL-SCI Corporation We are offering 3,715,000 shares of our common stock, par value $0.01 per share, at an offering |
|
| July 29, 2024 |
EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $10.8 MILLION OFFERING Vienna, Virginia – July 26, 2024 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the pricing of a be |
|
| July 29, 2024 |
CEL-SCI ANNOUNCES CLOSING OF $10.8 MILLION OFFERING EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $10.8 MILLION OFFERING Vienna, Virginia – July 29, 2024 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the closing of its |
|
| July 29, 2024 |
EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC 1 CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York July 26, 2024 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the "Agreement") sets forth the terms upon which ThinkEquity LLC ("ThinkEquity" or the "Placement Agent") shall b |
|
| July 29, 2024 |
EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT CEL-SCI CORPORATION Warrant Shares: Issue Date: June, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and unti |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| July 26, 2024 |
EXHIBIT 99 NEWS 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI’S PHASE 3 POPULATION ANALYSIS FOR UPCOMING CONFIRMATORY REGISTRATION STUDY IN HEAD & NECK CANCER DEMONSTRATES WELL BALANCED PATIENT POPULATION, CONFIDENCE IN CLINICAL RESULTS · Multikine, a true first-line cancer i |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| June 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 18, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| June 20, 2024 |
EXHIBIT 99 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI PRESENTS HEAD & NECK CANCER DATA AT IDDST ANNUAL CONGRESS IN BUDAPEST: RISK OF DEATH CUT IN HALF FOR PATIENTS TREATED WITH MULTIKINE IN THE TARGET POPULATION · Multikine significantly increases overall survival in patie |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SC |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| March 7, 2024 | ||
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| March 7, 2024 |
Annual Report 2023 2 CEL-SCI’s Corporation CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL |
|
| February 13, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 8, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 13, 2024 |
CEL-SCI ANNOUNCES CLOSING OF $7.75 MILLION PUBLIC OFFERING OF COMMON STOCK EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $7.75 MILLION PUBLIC OFFERING OF COMMON STOCK Vienna, VA, February 13, 2024 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today a |
|
| February 13, 2024 |
EXHIBIT 1.1 Execution Version UNDERWRITING AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC as Representative of the Several Underwriters 1 CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York February 8, 2024 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: The u |
|
| February 13, 2024 |
CEL-SCI ANNOUNCES PRICING OF $7.75 MILLION PUBLIC OFFERING OF COMMON STOCK EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $7.75 MILLION PUBLIC OFFERING OF COMMON STOCK Vienna, VA, February 9, 2024 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today an |
|
| February 9, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 3,875,000 Shares Common Stock CEL-SCI Corporation We are offering 3,875,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $2.00 per share. Our common stock is listed on the N |
|
| December 22, 2023 |
2023 Non-Qualified Stock Option Plan EXHIBIT 4(b) CEL-SCI CORPORATION 2023 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the "Plan") is intended to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for th |
|
| December 22, 2023 |
EXHIBIT 4(c) CEL-SCI CORPORATION 2023 STOCK BONUS PLAN l. Purpose. The purpose of this Stock Bonus Plan is to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for the successful conduct of its business, |
|
| December 22, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables S-8 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) 2,500,000 $ 2. |
|
| December 22, 2023 |
EXHIBIT 99 CEL-SCI CORPORATION Common Stock This Prospectus relates to shares (the "Shares") of common stock (the "Common Stock") of CEL-SCI Corporation which may be issued pursuant to certain employee compensation plans adopted by CEL-SCI. |
|
| December 22, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off |
|
| December 21, 2023 |
FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI CORPORATION (Exact |
|
| December 21, 2023 |
Policy relating to Recovery of Erroneously Awarded Compensation EXHIBIT 97 CEL-SCI CORPORATION Compensation Recovery Policy 1 TABLE OF CONTENTS Overview 3 Section 1. |
|
| November 20, 2023 |
CEL-SCI ANNOUNCES PRICING OF $5 MILLION OFFERING OF COMMON STOCK EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $5 MILLION OFFERING OF COMMON STOCK Vienna, VA, November 16, 2023 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced t |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 15, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission F |
|
| November 20, 2023 |
CEL-SCI ANNOUNCES CLOSING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK Vienna, VA, November 20, 2023 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today anno |
|
| November 20, 2023 |
EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC as Representative of the Several Underwriters 1 CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York November 15, 2023 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: The undersigned, CEL-S |
|
| November 16, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 2,490,000 Shares Common Stock CEL-SCI Corporation We are offering 2,490,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $2.00 per share. Our common stock is listed on the N |
|
| October 30, 2023 |
Extension of Employment Agreement with Geert Kersten (2023-2027) EXHIBIT 10.10 EXTENSION OF EMPLOYMENT AGREEMENT The parties hereby agree that the term of the Employment Agreement made by and between Geert Kersten and CEL-SCI Corporation as of August 31, 2019 is extended to August 31, 2027. All other terms of the Employment Agreement with Mr. Kersten dated August 31, 2019 remain the same. October 26, 2023 CEL-SCI CORPORATION By: /s/ Patricia Prichep Patricia B. |
|
| October 30, 2023 |
EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com NYSE American: CVM COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI Issues Letter to Shareholders View the letter: https://cel-sci.com/wp-content/uploads/2023/10/CEL-SCIshareholderletterfromCEOOct2023.pdf Vienna, VA: October 30, 2023 — CEL-SCI Corporati |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 26, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 24, 2023 |
8229 Boone Boulevard, Suite 802 EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com NYSE American: CVM COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023 ➢ Target patient po |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 23, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 28, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) ( Commission Fi |
|
| August 31, 2023 |
Extension of Employment Agreement with Patricia Prichep (2023-2027) EXHIBIT 10.10 EXTENSION OF EMPLOYMENT AGREEMENT The parties hereby agree that the term of the Employment Agreement made by and between Patricia B. Prichep and CEL-SCI Corporation as of August 31, 2019 is extended to August 31, 2027. All other terms of the Employment Agreement with Ms. Prichep dated August 31, 2019 remain the same. August 28, 2023 CEL-SCI CORPORATION By: /s/ Geert Kersten Geert R. |
|
| August 31, 2023 |
Extension of Employment Agreement with Eyal Talor (2023-2027) EXHIBIT 10.11 EXTENSION OF EMPLOYMENT AGREEMENT The parties hereby agree that the term of the Employment Agreement made by and between Eyal Talor and CEL-SCI Corporation as of August 31, 2019 is extended to August 31, 2027. All other terms of the Employment Agreement with Dr. Talor dated August 31, 2019 remain the same. August 28, 2023 CEL-SCI CORPORATION By: /s/Geert Kersten Geert R. Kersten, Chi |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SCI |
|
| July 20, 2023 |
CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING EXHIBIT 99 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING Vienna, VA, July 20, 2023 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previous |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 20, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| July 18, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 2,500,000 Shares Common Stock CEL-SCI Corporation We are offering 2,500,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus, at an offering price of $2.00 per share. Our common stock is listed on the NYSE American under the symbol |
|
| July 18, 2023 |
EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC as Representative of the Several Underwriters 1 CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York July 17, 2023 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Floor New York, New York 10004 Ladies and Gentlemen: The undersigned, CEL |
|
| July 18, 2023 |
CEL-SCI ANNOUNCES PRICING OF PUBLIC OFFERING EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF PUBLIC OFFERING Vienna, VA, July 17, 2023 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 17, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| July 17, 2023 | ||
| July 17, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus su |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 14, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| July 14, 2023 |
Gavin de Windt CEL-SCI Corporation (703) 506-9460 EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI CONCLUDES POSITIVE MEETING WITH U.S. FDA CONCERNING MULTIKINE’S APPROVAL FOR HEAD & NECK CANCER · FDA acknowledges the great need for improved treatments for head and neck cancer, particularly the locally a |
|
| July 12, 2023 |
EXHIBIT 99 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI REPORTS PHASE 3 TUMOR PD-L1 BIOMARKER DATA DEMONSTRATE MULTIKINE’S INCREASED EFFICACY AND POINTS TO POTENTIAL FOR COMBINATION WITH CHECKPOINT INHIBITORS FOR HEAD & NECK CANCER · Multikine significantly increases overall |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 11, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction (Commission File No.) (IRS Employer |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 23, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SC |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No |
|
| May 1, 2023 |
CEL-SCI ANNOUNCES $1.35 MILLION UNDERWRITTEN CONFIDENTIALLY MARKETED PUBLIC OFFERING OF COMMON STOCK EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES $1.35 MILLION UNDERWRITTEN CONFIDENTIALLY MARKETED PUBLIC OFFERING OF COMMON STOCK Vienna, VA, April 27, 2023 - CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunot |
|
| May 1, 2023 |
CEL-SCI CORPORATION 794,117 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) CEL-SCI CORPORATION 794,117 Shares of Common Stock We are offering 794,117 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $1.70 per share. Our common stock is listed on the NY |
|
| May 1, 2023 |
EX-1.1 2 cvmex11.htm UNDERWRITING AGREEMENT DATED EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI CORPORATION and SPARTAN CAPITAL SECURITIES, LLC as Representative of the Several Underwriters -1- CEL-SCI Corporation 8229 Boone Blvd. #802 Vienna, Virginia 22182 UNDERWRITING AGREEMENT New York, New York April 27, 2023 Spartan Capital Securities, LLC As Representative of the several Underwriters n |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 27, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| April 19, 2023 |
EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI TO PURSUE CANADA’S CONDITIONAL APPROVAL PATHWAY FOR MULTIKINE IN THE TREATMENT OF HEAD & NECK CANCER · Follows pre-submission meeting with Canada’s regulator Health Canada · Plans to pursue marketing approv |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction (Commission File No.) (IRS Employe |
|
| April 10, 2023 | ||
| April 10, 2023 |
Annual Report 2022 2 CEL-SCI Corporation CEL-SCI is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 8, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| March 9, 2023 |
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension EXHIBIT 99 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension · Presented at the 10th European Congress on Head & Neck Oncology · Six Different Efficacy Measures Demonstrate Benefits of Adding Multikine to Standard of C |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL |
|
| December 27, 2022 |
FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI CORPORATION (Exact |
|
| September 13, 2022 |
8229 Boone Boulevard, Suite 802 EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. |
|
| September 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 12, 2022 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission |
|
| August 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 19, 2022 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| August 22, 2022 |
EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com CEL-SCI CORPORATION ANNOUNCES PHASE 3 MULTIKINE® HEAD AND NECK CANCER RESULTS POSTED ON CLINICALTRIALS.GOV The “Proposed Indication” for Multikine that will be submitted to the FDA in a license application will be limited by certain eligibility criteria to patients who would be |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SCI |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 2, 2022 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| July 1, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-09l6344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and telephone number i |
|
| July 1, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables S-8 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) 3,800,000 $ 3. |
|
| July 1, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off |
|
| July 1, 2022 |
Non-Qualified Stock Option Plan EXHIBT 4(b) CEL-SCI CORPORATION 2022 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the ?Plan?) is intended to advance the interests of CEL-SCI Corporation (the ?Company?) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for the |
|
| July 1, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) $ 150,000,000 $92. |
|
| July 1, 2022 |
EX-99 6 cvmex99.htm CEL-SCI CORPORATION EXHIBIT 99 CEL-SCI CORPORATION Common Stock THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK. SEE “RISK FACTORS”. THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION, NOR HAS THE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. |
|
| July 1, 2022 |
File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 5 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 2836 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number |
|
| July 1, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock Rule 457(c) 1,079,483 $ 3. |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 13, 2022 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SC |
|
| April 29, 2022 |
ARS 1 cvmars.htm ARS |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 29, 2022 | ||
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL |
|
| December 21, 2021 |
FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI CORPORATION (Exact |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SCI |
|
| July 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 7, 2021 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 7, 2021 |
CEL-SCI CORPORATION ISSUES LETTER TO SHAREHOLDERS EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI CORPORATION ISSUES LETTER TO SHAREHOLDERS Vienna, VA, July 7, 2021 - CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders. Dear CEL-SCI shareholders: The purpose of this letter |
|
| July 2, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 1, 2021 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 29, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 28, 2021 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| June 9, 2021 |
CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA, June 8, 2021 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it has entered into an underwriting agreeme |
|
| June 9, 2021 |
(Subject to Completion, dated June 8, 2021) Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell the securities and |
|
| June 9, 2021 |
Exhibit 1.1 AMENDED and RESTATED UNDERWRITING AGREEMENT between CEL-SCI Corporation and KINGSWOOD CAPITAL MARKETS, division of Benchmark Investments, LLC, as Representative of the Several Underwriters 1 CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York June 8, 2021 Kingswood Capital Markets, division of Benchmark Investments, LLC As Representative of the several Underwriters named on S |
|
| June 9, 2021 |
CEL-SCI INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL TO $31.7 MILLION EXHIBIT 99.2 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL TO $31.7 MILLION Vienna, VA, June 8, 2021 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that, due to demand |
|
| June 9, 2021 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 8, 2021 CEL SCI CORP (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No.) (IR |
|
| June 9, 2021 |
TERM SHEET CEL-SCI CORPORATION Public Offering of Common Stock Filed pursuant to Rule 433 Registration Statement No.: 333-226558 Issuer Free Writing Prospectus dated June 8, 2021 Relating to Preliminary Prospectus Supplement dated June 8, 2021 TERM SHEET CEL-SCI CORPORATION Public Offering of Common Stock This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the accompanying prospectus, |
|
| June 9, 2021 |
CEL-SCI CORPORATION 1,400,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 24, 2018) CEL-SCI CORPORATION 1,400,000 Shares of Common Stock We are offering 1,400,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $22.62 per share. Our common stock is listed on |
|
| May 18, 2021 |
ARS 1 cvmars.htm ARS |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SC |
|
| February 12, 2021 |
Quarterly Report - QUARTELRY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL |
|
| January 15, 2021 |
POS AM 1 cvmposam.htm AMENDMENT NO 4 File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 4 Registration Statement Under THE SECURITIES ACT OF 1933 Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and tel |
|
| December 31, 2020 |
Quarterly Report - JUNE 30, 2020 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 2) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Numb |
|
| December 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| December 30, 2020 |
Quarterly Report - DECEMBER 31, 2019 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File |
|
| December 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 23, 2020 CEL SCI CORP (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No. |
|
| December 29, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-11889 CEL-SCI CORPORATION (Exac |
|
| December 9, 2020 |
EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI Corporation and KINGSWOOD CAPITAL MARKETS, division of Benchmark Investments, Inc., as Representative of the Several Underwriters 1 CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York December 8, 2020 Kingswood Capital Markets, division of Benchmark Investments, Inc. As Representative of the several Underwriters named on Schedule 1 attac |
|
| December 9, 2020 |
Entry into a Material Definitive Agreement, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 8, 2020 CEL SCI CORP (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| December 9, 2020 |
CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA, December 8, 2020 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it has entered into an underwriting agree |
|
| December 9, 2020 |
CEL-SCI CORPORATION 1,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 24, 2018) CEL-SCI CORPORATION 1,000,000 Shares of Common Stock We are offering 1,000,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $14.65 per share. Our common stock is listed on |
|
| December 9, 2020 |
Issuer General Use Free Writing Prospectus Issuer General Use Free Writing Prospectus Filed pursuant to Rule 433 Registration Statement No. |
|
| December 9, 2020 |
(Subject to Completion, dated December 8, 2020) Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell the securities and |
|
| December 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 7, 2020 CEL SCI CORP (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| December 7, 2020 |
EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI Announces Update on Phase 3 Cancer Trial Results Data lock is complete, final statistical analysis being conducted Vienna, VA, December 7, 2020 - CEL-SCI Corporation (NYSE American: CVM) announced today tha |
|
| October 30, 2020 |
Material Modification to Rights of Security Holders - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 30, 2020 CEL SCI CORP (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| October 30, 2020 |
Shareholders Rights Agreement, as Amended EX-4 2 cvmex4.htm SHAREHOLDER RIGHTS AGREEMENT Exhibit 4 SHAREHOLDER RIGHTS AGREEMENT (As Amended) CEL-SCI CORPORATION 8229 Boone Boulevard, Suite 802 Vienna, Virginia 22182 TABLE OF CONTENTS SECTION PAGE Section 1. Certain Definitions 2 Section 2. Appointment of Rights Agent 6 Section 3. Issue of Right Certificates 6 Section 4. Form of Right Certificates 8 Section 5. Countersignature and Registra |
|
| August 11, 2020 |
Quarterly Report - AMENDED QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No.1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Numbe |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SCI |
|
| July 2, 2020 |
Registration Statement - REGISTRATION STATEMENT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and telephone number i |
|
| July 2, 2020 |
EX-10.11 4 cvmex1011.htm SECURITIES PURCHASE AGREEMENT WITH ERGOMED EXHIBIT 10.11 SECURITIES PURCHASE AGREEMENT between CEL-SCI CORPORATION and ERGOMED plc dated as of June 29, 2020 1 TABLE OF CONTENTS ARTICLE I DEFINITIONS 3 ARTICLE II PURCHASE AND SALE 5 Section 2.01 Purchase and Sale. 5 Section 2.02 Transactions Effected at the Closing. 5 Section 2.03 Closing. 6 ARTICLE III REPRESENTATIONS AND |
|
| July 2, 2020 |
Exhibit 10.10 May 27, 2020 CONFIDENTIAL Mr. Geert R. Kersten Director and Chief Executive Officer CEL-SCI Corporation 8229 Boone Boulevard, Suite 802 Vienna, Virginia 22182 Re: Warrant Solicitation Engagement Dear Geert: The purpose of this engagement letter (the “Warrant Solicitation Agreement” or “Agreement”)) is to set forth our agreement pursuant to which Dawson James Securities, Inc. (“Dawson |
|
| July 1, 2020 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 25, 2020 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 01-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 26, 2020 |
Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 26, 2020 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 26, 2020 |
Exhibit 4(f) COMMON STOCK PURCHASE WARRANT SERIES YY CEL-SCI CORPORATION Warrant Shares: Issuance Date: June 26, 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the “Initial Exercise Date” and on or prior to the close of business on the “Termination Date” but not thereafter, to subscribe for and purchase from CEL-SCI Corporation, a Colorado corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock. |
|
| May 26, 2020 |
Exhibit 4(g) COMMON STOCK PURCHASE WARRANT SERIES XX CEL-SCI CORPORATION Warrant Shares: Issuance Date: June 11, 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the “Initial Exercise Date” and on or prior to the close of business on the “Termination Date” but not thereafter, to subscribe for and purchase from CEL-SCI Corporation, a Colorado corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock. |
|
| May 26, 2020 |
CEL-SCI CORPORATION Series V Warrants PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(3) (To Prospectus Supplement Registration No. |
|
| May 8, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SC |
|
| April 24, 2020 |
(b) - 2020 Non-Qualified Stock Option Plan Exhibit 4(b) CEL-SCI CORPORATION 2020 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the "Plan") is intended to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for th |
|
| April 24, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off |
|
| April 24, 2020 |
99 - Additional Exhibits (Re-Offer Prospectus) Exhibit 99 CEL-SCI CORPORATION Common Stock THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK. |
|
| April 17, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 17, 2020 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| April 15, 2020 |
CEL-SCI CORPORATION 8229 Boone Blvd. #802 Vienna, VA 22182 (703) 506-9460 April 15, 2020 Irene Paik Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: CEL-SCI Corporation Form S-1 SEC File No. 333-327623 CEL-SCI Corporation (the “Company”) requests that the effective date of the above captioned Registration Statement be accelerated to Monday, April 20, 2020 at 2:00 P.M. E |
|
| April 9, 2020 |
Exhibit 10.9 |
|
| April 9, 2020 |
CVM / CEL-SCI Corp. S-1 - Registration Statement - REGISTRATION STATEMENT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and telephone number i |
|
| March 30, 2020 |
CVM / CEL-SCI Corp. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| March 24, 2020 |
CEL-SCI INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL TO $7.7 MILLION EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL TO $7.7 MILLION Vienna, VA, March 24, 2020 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that, due to demand, the underw |
|
| March 24, 2020 |
CEL-SCI CORPORATION 630,500 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 24, 2018) CEL-SCI CORPORATION 630,500 Shares of Common Stock We are offering 630,500 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $12.22 per share. Our common stock is listed on the |
|
| March 24, 2020 |
CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA, March 23, 2020 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced today that it has entered into an underwriting agreement wi |
|
| March 24, 2020 |
Issuer General Use Free Writing Prospectuses Issuer General Use Free Writing Prospectuses Filed pursuant to Rule 433 Registration Statement No. |
|
| March 24, 2020 |
(Subject to Completion, dated March 23, 2020) Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell the securities and |
|
| March 24, 2020 |
Issuer General Use Free Writing Prospectuses Issuer General Use Free Writing Prospectuses Filed pursuant to Rule 433 Registration Statement No. |
|
| March 24, 2020 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 23, 2020 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File |
|
| March 24, 2020 |
EXHIBIT 1 AMENDED AND RESTATED UNDERWRITING AGREEMENT between CEL-SCI Corporation and AEGIS CAPITAL CORP. |
|
| March 17, 2020 |
CVM / CEL-SCI Corp. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| March 13, 2020 |
CVM / CEL-SCI Corp. POS AM - - POS AM File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 3 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Ad |
|
| March 13, 2020 |
Exhibit 3(d) BYLAWS OF CEL-SCI CORPORATION ARTICLE I OFFICES Section l. Offices: The principal office of the Corporation shall be determined by the Board of Directors, and the Corporation shall have other offices at such places as the Board of Directors may from time to time determine. ARTICLE II STOCKHOLDER'S MEETINGS Section l. Place: The place of stockholders' meetings shall be the principal of |
|
| March 6, 2020 |
CVM / CEL-SCI Corp. POS AM - - POS AM File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 2 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Ad |
|
| March 4, 2020 | ||
| March 4, 2020 |
CVM / CEL-SCI Corp. DEFA14A - - DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| March 4, 2020 |
CVM / CEL-SCI Corp. DEF 14A - - DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| March 4, 2020 | ||
| February 21, 2020 |
CVM / CEL-SCI Corp. POS AM - - POS AM File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Ad |
|
| February 20, 2020 |
CVM / CEL-SCI Corp. S-1/A - - S-1/A File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Ad |
|
| February 10, 2020 |
CVM / CEL-SCI Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL |
|
| February 3, 2020 |
CVM / CEL-SCI Corp. POS AM - - POS AM SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including z |
|
| January 24, 2020 |
CVM / CEL-SCI Corp. S-8 - - REGISTRATION STATEMENT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off |
|
| January 24, 2020 |
Additional Exhibits (Re-Offer Prospectus) EXHIBIT 99 CEL-SCI CORPORATION Common Stock THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK. |
|
| January 24, 2020 |
EXHIBIT 4(c) CEL-SCI CORPORATION 2019 STOCK COMPENSATION PLAN CEL-SCI Corporation (“the Company”) hereby adopts this Stock Compensation Plan. |
|
| January 24, 2020 |
(b) - 2019 Non-Qualified Stock Option Plan EXHIBIT 4(b) CEL-SCI CORPORATION 2019 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the "Plan") is intended to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for th |
|
| December 26, 2019 |
CEL-SCI CORPORATION Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 24, 2018) CEL-SCI CORPORATION Shares of Common Stock We are offering 606,395 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $9.07 per share of common stock. Our common stock is listed |
|
| December 26, 2019 |
EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI Corporation and AEGIS CAPITAL CORP., as Representative of the Several Underwriters CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York December 23, 2019 Aegis Capital Corp. As Representative of the several Underwriters named on Schedule 1 attached hereto 810 Seventh Avenue, 18th Floor New York, New York 10019 Ladies and Gentlemen: The un |
|
| December 26, 2019 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 23, 2019 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission F |
|
| December 26, 2019 |
CEL-SCI PRICES $5.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI PRICES $5.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK Vienna, VA, December 24, 2019 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an unde |
|
| December 23, 2019 |
(Subject to Completion, dated December 23, 2019) Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell the securities and |
|
| December 23, 2019 |
CVM / CEL-SCI Corp. 10-K/A - Annual Report - FORM 10-K/A FORM 10-K/A (Amendment No.1) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019. OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL- |
